Merck Says Health Canada Approves Keytruda Combination As Neoadjuvant Treatment For A Type Of Bladder Cancer
MRK•Health Canada approves Keytruda combination for bladder cancer treatment
Aug. 5 (Reuters) - Merck & Co Inc MRK.N:
- Health Canada approves Keytruda® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment
Source text: ID:nCNWb15jca
Further company coverage: MRK.N
